These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29989040)

  • 21. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    Singh AK; Carroll K; McMurray JJV; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; DiMino TL; Kler L; Meadowcroft AM; Taft L; Perkovic V;
    N Engl J Med; 2021 Dec; 385(25):2313-2324. PubMed ID: 34739196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Fu X; Wei R; Liu YN; Liu WJ
    Front Pharmacol; 2020; 11():573645. PubMed ID: 33597868
    [No Abstract]   [Full Text] [Related]  

  • 25. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
    Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
    Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).
    Gang S; Khetan P; Varade D; Chinta VR; Mavani S; Gupta U; Reddy SVK; Rajanna S; Jeloka T; Ruhela V; Kansagra K; Kanani P; Bhatt J; Zala K;
    Am J Nephrol; 2022; 53(5):343-351. PubMed ID: 35462369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease.
    Johansen KL; Cobitz AR; Singh AK; Macdougall IC; Lopes RD; Obrador GT; Kovesdy CP; Israni R; Jha V; Okoro T; Sprys M; Jolly S; Lindsay AC; Bhatt P; Camejo RR; Keeley T; Cizman B; Wheeler DC
    Kidney Int; 2023 Jun; 103(6):1180-1192. PubMed ID: 36868377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
    Kanai H; Nangaku M; Nagai R; Okuda N; Kurata K; Nagakubo T; Endo Y; Cobitz A
    Ther Apher Dial; 2021 Dec; 25(6):979-987. PubMed ID: 33964183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
    Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A
    Nephrol Dial Transplant; 2022 Apr; 37(5):960-972. PubMed ID: 33744933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
    Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
    Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.
    Ali Fadlalmola H; Al-Sayaghi KM; Al-Hebshi AA; Alhujaily M; Alyamani AO; Alem AA; Syrafi MH; Alem S; Farhat AH; Mohamed FA; Abdalrahman HH; Abdelmalik MA; Abdalrhman NM; Eltayeb AM
    Pan Afr Med J; 2024; 47():114. PubMed ID: 38828426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States.
    Weinhandl ED; Eggert W; Hwang Y; Gilbertson DT; Petersen J
    Kidney Int Rep; 2023 Dec; 8(12):2616-2624. PubMed ID: 38106574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Molidustat in the Treatment of Anemia in CKD.
    Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.